Asset profile
Rongliflozin
Small molecule
Evidence outlook · lead readout
NCT05427682 · Diabetes Mellitus, Type 2
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05427682: A non-randomized, open-label, parallel-group pharmacokinetic study of rongliflozin in 32 participants with normal or impaired liver function. With no randomization, no blinding, no comparator arm, and no results posted to the registry, this is weak evidence.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.